Journey Medical Corp (DERM)
3.45
-0.17
(-4.70%)
USD |
NASDAQ |
May 17, 16:00
3.45
0.00 (0.00%)
After-Hours: 20:00
Journey Medical Cash from Financing (TTM): -3.219M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -3.219M |
December 31, 2023 | -4.804M |
September 30, 2023 | -23.07M |
June 30, 2023 | -8.057M |
March 31, 2023 | 5.142M |
Date | Value |
---|---|
December 31, 2022 | 16.46M |
September 30, 2022 | 47.31M |
June 30, 2022 | 54.49M |
March 31, 2022 | 54.99M |
December 31, 2021 | 53.02M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-23.07M
Minimum
Sep 2023
54.99M
Maximum
Mar 2022
19.23M
Average
10.80M
Median
Cash from Financing (TTM) Benchmarks
Fortress Biotech Inc | 38.41M |
Stereotaxis Inc | 0.055M |
GT Biopharma Inc | 6.268M |
Cara Therapeutics Inc | 36.91M |
FibroGen Inc | 91.10M |